Research progress of biomarkers in immune-related adverse events caused by immune checkpoint inhibitors
10.3760/cma.j.cn114015-20240729-00656
- VernacularTitle:免疫检查点抑制剂相关不良事件的生物标志物研究进展
- Author:
Yiheng TANG
1
;
Dachuan CAI
1
Author Information
1. 重庆医科大学附属第二医院感染科，重庆医科大学感染性疾病分子生物学教育部重点实验室，重庆医科大学病毒性肝炎研究所，重庆 400010
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Biomarkers, pharmacological;
Immunotherapy;
Immune-related adverse events;
Biomarkers
- From:
Adverse Drug Reactions Journal
2025;27(4):232-237
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) are widely used in the treatment of various malignant tumors. While achieving therapeutic benefits, immune-related adverse events (irAEs) caused by ICIs have also drawn clinical attention. irAEs can affect almost all organs in the body, and the diversity of clinical manifestations increases the difficulty for clinicians and pharmacists to diagnose and intervene. Therefore, finding reliable biomarkers that can accurately predict and diagnose irAEs has significant clinical value. This article reviews the research progress of biomarkers of ICIs-related adverse events, providing a reference for the safe application of these drugs in clinical treatment.
